Tiziana Life Sciences

Our Company

Tiziana Life Sciences is a NASDAQ listed (NASDAQ:TLSA) clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and neuroinflammatory. Our clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer’s, and ALS. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.

Company Background

  • Our mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases.
  • Our lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Foralumab is the only fully human anti-CD3 monoclonal antibody under clinical development and is expected to minimize adverse immune responses in patients.
  • Tiziana has submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival.
  • We employ a lean and virtual research and development model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes.

Corporate Strategy

  • Continue the clinical development of intranasal administration of Foralumab for neurodegenerative disease indications:
    • Secondary Progressive, Multiple Sclerosis
    • Alzheimer’s
    • Amyotrophic Lateral Sclerosis (ALS)
  • Commence Phase 2 clinical trial in 2024 after successfully receiving our Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients.
  • Submit an Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients.
  • Seek orphan drugs fast track or breakthrough designation for our product candidates where warranted.